Analysis

Fairly Valued Defensive Stocks: J&J, Coca-Cola, P&G in Focus

Johnson & Johnson, Coca-Cola, and Procter & Gamble ended higher on Friday, but their valuations suggest they are fairly priced. Upcoming earnings calls will be crucial as the companies navigate litigation, tariffs, and input cost pressures.

Daniel Marsh · · · 3 min read · 3 views
Fairly Valued Defensive Stocks: J&J, Coca-Cola, P&G in Focus
Mentioned in this article
JNJ $240.87 +1.07% KO $82.62 +0.11% PG $149.61 +0.86%

Defensive dividend stocks joined the broader market rally on Friday, with the S&P 500 rising 0.5% and the Dow Jones Industrial Average gaining 0.7%. Among the notable gainers were Johnson & Johnson (JNJ), Coca-Cola (KO), and Procter & Gamble (PG), which closed at $240.87, $82.62, and $149.61, respectively. However, with price-to-earnings ratios of approximately 27.9, 26.0, and 21.9, these stocks appear fairly valued rather than deeply discounted.

Johnson & Johnson: Healthcare Resilience and Dividend Growth

Johnson & Johnson continues to attract dividend-focused investors seeking exposure outside consumer staples. In April, the company raised its quarterly dividend by 3.1% to an annualized $5.36 per share, marking its 64th consecutive year of dividend growth. At Friday's closing price, the yield stands at about 2.2%. The company's first-quarter results showed strong momentum, with sales jumping 9.9% to $24.1 billion and adjusted earnings per share reaching $2.70. Management has also highlighted the planned $1 billion acquisition of Firefly Bio as a strategic move to bolster its oncology pipeline.

Despite these positives, bears point to valuation concerns and execution risks. With a P/E ratio near 28, there is limited room for error. The company's own filings cite potential headwinds from patent disputes, product pipeline challenges, litigation, and government actions. Investors will closely watch the July 15 second-quarter earnings call for signs that oncology, immunology, and MedTech segments can sustain growth and offset the impact of Stelara biosimilar competition and legal uncertainties. At current levels, J&J trades at a fair-to-rich valuation, offering a reliable dividend but with exposure to earnings deceleration.

Coca-Cola: Steady Cash Flow, Premium Valuation

Coca-Cola maintains its position as a premier consumer staples dividend stock, underpinned by strong cash flow from its brand portfolio and global bottling network. The board approved its 64th consecutive annual dividend increase in February, raising the quarterly payout by about 4% to $0.53 per share. The next dividend of $0.53 is payable July 1 to shareholders of record as of June 15. Based on Friday's close, the annualized payout of $2.12 yields approximately 2.6%.

The company's first-quarter performance was robust: net revenue climbed 12%, organic revenue rose 10%, and comparable earnings per share increased 18% to $0.86. However, with shares trading at about 26 times earnings and management guiding for 4% to 5% organic revenue growth and 8% to 9% earnings per share growth in 2026, investors may be paying a premium for quality. Coca-Cola has also flagged higher costs, increased marketing spending, and tax-related uncertainties. The upcoming second-quarter results will be pivotal; if they align with guidance, the stock appears fairly priced rather than a bargain.

Procter & Gamble: Highest Yield Among the Trio

Procter & Gamble offers the highest current yield among the three, following 70 consecutive years of dividend increases and 136 years of uninterrupted payouts. The latest quarterly dividend of $1.0885 annualizes to about $4.35, yielding close to 2.9% based on Friday's close. The company reported strong demand for its everyday essentials in the fiscal third quarter, with net sales up 7% to $21.2 billion, organic sales rising 3%, and diluted earnings per share increasing 6% to $1.63. P&G also returned $3.2 billion to shareholders through dividends and share repurchases.

However, margin pressures are a concern. The company has identified $150 million in after-tax commodity cost headwinds and $400 million in tariff-related expenses for fiscal 2026. As a result, management now expects earnings per share to come in at the low end of its guidance range. This highlights how even reliable dividend stocks can face valuation compression when costs threaten future profits. The July 29 fiscal fourth-quarter earnings call will be the next major event, with investors seeking updates on cost management, pricing power, and capital return plans. P&G remains the most income-driven play among the three, but risks related to efficiency and pricing actions persist.

Market Context and Outlook

The defensive nature of these stocks has provided a safe harbor during market volatility, but their current valuations suggest limited upside without stronger earnings catalysts. The upcoming earnings calls for J&J (July 15), Coca-Cola (late July), and P&G (July 29) will be critical in determining whether these companies can justify their premiums. Investors should weigh the steady income against the risks of litigation, input cost inflation, and tariff impacts that could weigh on future performance.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →